ArticleFrontiers in pediatrics2026
Clinical characteristics and risk factors of acute cutaneous graft-vs.-host disease following allogeneic hematopoietic stem cell transplantation in pediatric acute myeloid leukemia: a single-center retrospective study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze clinical characteristics and risk factors of acute cutaneous graft-vs.-host disease (GVHD) in pediatric acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), providing evidence for clinical risk stratification and individualized prophylaxis. Methods: A retrospective cohort study included pediatric AML patients who underwent their first allo-HSCT at Hunan Children's Hospital between July 1, 2022 and December 31, 2024. Demographic, disease-related, donor-recipient matching, transplant procedure, and supportive care data were collected. The primary outcome was acute cutaneous GVHD within 100 days post-transplant. Univariate analysis identified potential risk factors, and multivariate logistic regression confirmed independent predictors, with sensitivity analysis verifying robustness. Results: Acute cutaneous GVHD occurred in 27 pediatric patients (38.6%), including grade I (14.8%, 4/27), II (59.3%, 16/27), and III (25.9%, 7/27) cases. Multivariate analysis showed HLA mismatch at ≥2/10 alleles (OR = 4.26, 95%CI:1.68-10.82, Conclusion: Poor HLA matching, refractory/relapsed disease pre-transplant, and MAC increase the risk of acute cutaneous GVHD in pediatric AML patients after allo-HSCT. The risk factors identified in this study are helpful for identifying high-risk pediatric AML patients before transplantation, providing a basis for implementing individualized GVHD prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.